Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Montanide refers to a family of water-in-oil emulsion adjuvants, most notably Montanide ISA 51 and Montanide ISA 720, used to enhance immune responses in vaccine formulations. It acts primarily by stimulating the immune system to generate stronger and more durable responses against co-administered antigens through a depot effect, enhanced antigen presentation, and activation of innate immunity, promoting both humoral and cellular immune responses.
Montanide's adjuvant effect is based on several immunological mechanisms: - Depot Effect: The water-in-oil emulsion forms a depot at the injection site, allowing for sustained release of antigen over time. This prolonged exposure increases the duration during which antigen-presenting cells (APCs) can interact with the antigen. - Enhanced Antigen Presentation: By facilitating slow release and local concentration of antigens, Montanide increases uptake by APCs such as dendritic cells. These APCs process the antigen and present it on MHC class II molecules to T cells, initiating adaptive immunity. - Activation of Innate Immunity: The emulsion induces local inflammation at the injection site, recruiting immune cells including macrophages, dendritic cells, B lymphocytes, and T lymphocytes. This leads to upregulation of cytokines/chemokines that further stimulate both innate and adaptive arms. - Promotion of Humoral Response: Studies show that Montanide-adjuvanted vaccines induce higher titers of antibodies with greater avidity for their target antigens compared to some other adjuvants. In particular, Montanide ISA 720 has been shown in animal models to promote differentiation toward plasma cell lineages through gene signatures associated with heme biosynthesis in B lymphocytes. - Mixed Th1/Th2 Cytokine Profile: Immunization with Montanide-based formulations often results in a mixed Th1/Th2 cytokine response profile—supporting both cellular (T cell-mediated) and humoral (antibody-mediated) immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Montanide.